Trial Profile

A Clinical Study of Two Doses of a Selective p38 MAP Kinase Inhibitor, VX-745, to Evaluate the Effects of 12-Week Oral Twice-Daily Dosing on Amyloid Plaque Load as Assessed by Quantitative Dynamic 11C-PiB Positive Emission Tomography (PET) Amyloid Scanning

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

03 Apr 2023 According to an EPI Pharmaceuticals media release, company today announced oral presentation by academic investigators from Amsterdam University Medical Center of neuroimaging results from this clinical study in patients with early Alzheimer's disease (AD) at International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) 2023, which took place virtually and in person Mar 28-Apr 1, 2023, in Gothenburg, Sweden.
02 Dec 2022 Results presented in an EPI Pharmaceuticals Media Release.
02 Dec 2022 According to an EPI Pharmaceuticals media release, data presented at the 15th Annual Clinical Trials in Alzheimer's disease (CTAD) meeting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com